Geode Capital Management’s Raptor Pharmaceutical RPTP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-624,829
| Closed | -$5.6M | – | 4134 |
|
|
2016
Q3 | $5.6M | Buy |
624,829
+30,937
| +5% | +$220K | ﹤0.01% | 1898 |
|
|
2016
Q2 | $3.19M | Buy |
593,892
+20,810
| +4% | +$107K | ﹤0.01% | 2177 |
|
|
2016
Q1 | $2.64M | Buy |
573,082
+37,740
| +7% | +$152K | ﹤0.01% | 2261 |
|
|
2015
Q4 | $2.78M | Sell |
535,342
-34,612
| -6% | -$201K | ﹤0.01% | 2261 |
|
|
2015
Q3 | $3.45M | Buy |
569,954
+53,363
| +10% | +$654K | ﹤0.01% | 2086 |
|
|
2015
Q2 | $8.16M | Buy |
516,591
+93,841
| +22% | +$1.14M | ﹤0.01% | 1562 |
|
|
2015
Q1 | $4.6M | Buy |
422,750
+27,910
| +7% | +$285K | ﹤0.01% | 1902 |
|
|
2014
Q4 | $4.15M | Buy |
394,840
+43,725
| +12% | +$427K | ﹤0.01% | 1923 |
|
|
2014
Q3 | $3.37M | Buy |
351,115
+13,764
| +4% | +$141K | ﹤0.01% | 2010 |
|
|
2014
Q2 | $3.9M | Buy |
337,351
+14,337
| +4% | +$131K | ﹤0.01% | 1940 |
|
|
2014
Q1 | $3.23M | Buy |
323,014
+8,300
| +3% | +$120K | ﹤0.01% | 2049 |
|
|
2013
Q4 | $4.1M | Buy |
314,714
+41,368
| +15% | +$570K | ﹤0.01% | 1848 |
|
|
2013
Q3 | $4.08M | Buy |
273,346
+31,416
| +13% | +$376K | ﹤0.01% | 1704 |
|
|
2013
Q2 | $2.26M | Hold |
241,930
| – | – | ﹤0.01% | 1962 |
|
Geode Capital Management's RPTP Position: Q4 2016 in Review
Geode Capital Management sold out of Raptor Pharmaceutical (RPTP) in Q4 2016, closing a stake of 624,829 shares — an estimated $5.6M sold.
Geode Capital Management first reported a position in RPTP in Q2 2013 and held it in 14 quarters. The position peaked at $8.16M in Q2 2015. 0 funds tracked by Wall St. Rank hold RPTP as of Q4 2016.
- Geode Capital Management reported no remaining Raptor Pharmaceutical position as of Q4 2016 after selling out during the quarter.
- Geode Capital Management sold 624,829 Raptor Pharmaceutical shares in Q4 2016, an estimated $5.6M.
- Geode Capital Management first reported a position in Raptor Pharmaceutical in Q2 2013 and held it in 14 quarters.
- Geode Capital Management's Raptor Pharmaceutical position peaked at $8.16M in Q2 2015.
- 0 funds tracked by Wall St. Rank held Raptor Pharmaceutical as of Q4 2016.
Based on Geode Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.